Skip to main content

Table 2 Median 3-year overall survival (OS)/disease free survival (DFS) and median OS/DFS in months in previously diagnosed AEL patients depending on subtypes and cytogenetic risk group (MRC and IPSS criteria)

From: An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

Parameter Median
3-year OS
Median OS (Months) P Median
3-year DFS
Median DFS (Months) P
Subtype
 MDS 56% 44.6 0.563 75.1% n.r. 0.538
 AML 64.4% n.r. 60.7% n.r.
Cytogenetics
 Intermediate MRC category 62.2% n.r <0.0001 71.5% n.r 0.008
 Unfavorable MRC category 12% 5.03 25% 5.3
 Good IPSS category 56.9% n.r 0.045 69.3% n.r 0.099
 Intermediate IPSS category 75% n.r 85.7% n.r
 Adverse IPSS category 13.3% 11.8 25% 5.33
  1. Abbreviation: IPSS International Prognostic Scoring System, MRC Medical Research Council